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Abstract 
Background: Diffuse malignant peritoneal mesothelioma (DMPM) is a rare and locally aggressive disease. DMPM 
prognosis is dismal, mainly due to the lack of effective treatment options and the development of new therapeutic 
strategies is urgently needed. In this context, novel immunotherapy approaches can be explored in an attempt to 
improve DMPM patients’ survival.
Methods: We tested the efficacy of CpG-oligodeoxynucleotides (CpG-ODN), synthetic DNA sequences recognized 
by Toll-like receptor 9 and able to induce innate/adaptive immune response, in two DMPM orthotopic xenografts 
(MesoII and STO), which properly recapitulate the dissemination pattern of the disease in the peritoneal cavity. Severe 
combined immunodeficiency mice carrying DMPM xenografts were treated at different stages of tumor development 
with i.p. delivered CpG-ODN1826 for 4 weeks. CpG-ODN1826-induced modulation in the composition of peritoneal 
immune infiltrate was assessed by flow cytometry.
Results: When administered to early-stage tumors (i.e., 4 days after i.p. DMPM cell injection in mice), the agent exhib-
ited impressive efficacy against MesoII by completely inhibiting tumor take and ascites development (no evidence 
of tumor masses and ascites in 6/6 mice at necropsy), and also impaired STO tumor take and growth (4/6 tumor-free 
mice; i.p. tumor masses reduced by 94 % in the 2 remaining mice, P = 0.00005). Interestingly, when tested against 
late-stage STO tumors (i.e., 11 days after i.p. DMPM cell injection in mice), CpG-ODN1826 was still able to reduce 
the growth of i.p. tumor masses by 66 % (P = 0.0009). Peritoneal washings of tumor-bearing mice revealed a strong 
increase of macrophage infiltration together with a decrease in the presence of B-1 cells and a reduced IgM concen-
tration after CpG-ODN1826 treatment.
Conclusions: Our results indicate that locally administered CpG-ODN1826 is able to markedly affect the growth of 
both early- and late-stage DMPM orthotopic xenografts in the absence of severe side effects, and suggest a possible 
clinical role for the agent in the therapy of DMPM.
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Background
Diffuse malignant peritoneal mesothelioma (DMPM) is 
an uncommon malignancy that develops from the meso-
thelial cells lining the peritoneal cavity and accounts 
for 10–20  % of all mesotheliomas [1]. Although locally 
invasive rather than metastatic, DMPM is a rapidly fatal 
disease. Standard therapy with palliative surgery and sys-
temic or intra-peritoneal (i.p.) chemotherapy is associated 
with a median survival of about 1  year [2]. Although in 
recent years an integrated approach that combines cytore-
ductive surgery (CRS) with perioperative hyperthermic 
i.p. chemotherapy (HIPEC) has improved median survival 
to 4–5  years [3], approximately half of treated patients 
experience relapse [4]. Thus, it is mandatory to develop 
novel strategies to optimize the management of recurrent 
DMPM patients and to offer valid alternative therapeutic 
options to patients who cannot undergo CRS +  HIPEC 
due to advanced stage of disease. In this context, novel 
immunotherapy approaches can be explored in an 
attempt to improve DMPM patients’ survival.
Toll-like receptors (TLR), which are critically impor-
tant in detecting pathogens, are potent activators of 
immune response under consideration for cancer immu-
notherapy [5, 6]. One of the most promising targets is 
TLR9, which is activated by synthetic oligodeoxynucleo-
tides (ODN) containing unmethylated CpG motifs (CpG-
ODN). Local delivery of CpG-ODN has been explored as 
a novel immunotherapy approach for cancers suitable for 
drug injection at the tumor site [5].
Immune cells directly or indirectly activated by CpG-
ODN treatment predominantly belong to the innate 
immune system, such as natural killer (NK) cells, mac-
rophages, neutrophils, monocytes and dendritic cells. 
Most of these cells require a local activation to exert their 
effector activity, unlike adaptive immune cells which can 
reach the target wherever they are activated, and need to 
be repeatedly stimulated, since their activity is generally 
reduced rapidly after mediating their effector functions [7].
The peritoneal cavity is characterized by a massive pres-
ence of innate immune cells as active biosensors against 
invading pathogens. These cells may provide a powerful 
tool for eradicating DMPM, since their antitumor activ-
ity can be stimulated by repeated local administrations of 
CpG-ODN. Here, we evaluated the efficacy of i.p. CpG-
ODN1826 against two DMPM orthotopic xenograft mod-
els in severe combined immunodeficiency (SCID) mice. 
The experimental results show that the agent significantly 
impaired take and growth of both DMPM models.
Methods
Cell lines
DMPM cell lines (MesoII and STO), which were 
established from surgical specimens of patients who 
underwent surgery at the Fondazione IRCCS Istituto 
Nazionale dei Tumori (INT) of Milan, were cultured as 
previously reported [8]. Cell lines were tested fortnightly 
for the absence of Mycoplasma and periodically moni-
tored for DNA profile of short tandem repeats by the 
AmpFISTR Identifiler PCR amplification kit (Applied 
Biosystems, Carlsbad, CA, USA). Both cell lines were last 
tested in December 2014.
In vivo studies
The in  vivo antitumor activity of purified, phospho-
rothioated CpG-ODN1826 (5′-TCCATGACGTTC-
CTGACGTT-3′; TriLinK Biotechnologies, San Diego, 
CA, USA) was assessed on DMPM cells orthotopically 
xenotransplanted into 8–10 weeks-old female SCID mice 
(Charles River, Calco, Italy). Experiments were approved 
by the Ethics Committee for Animal Experimentation of 
INT, according to reported guidelines [9]. The origin of 
orthotopic xenografts was authenticated through micros-
atellite analysis by the AmpFISTR Identifiler PCR Ampli-
fication Kit.
Orthotopic models were generated by injecting 
2.5 × 107 and 1 × 107 exponentially growing MesoII and 
STO cells, respectively, suspended in 500 µl saline in the 
peritoneum of SCID mice. The day after cell injection, 
mice were randomized (6–10 mice/group) to receive 
saline or CpG-ODN1826 delivered i.p. at 20  µg/mouse, 
every day for five days a week for four weeks (qdx5/
wx4w). CpG-ODN1826 treatment started 4  days (STO 
and MesoII early-stage tumors) or 11  days (STO late-
stage tumors) after cell injection (Fig. 1).
MesoII cell-injected mice developed hemorrhagic 
ascites in  >40  days. The animals were inspected and 
weighed daily, and sacrificed as ascites became evident 
(Fig.  1). The ratio of the median day of ascites onset in 
treated over control mice (T/C)  ×  100 was calculated. 
Conversely, STO cells did not develop ascites. The ani-
mals were sacrificed the day after the last CpG-ODN1826 
treatment (Fig.  1) and necropsy was performed to 
observe tumor spread in the abdominal cavity. Solid i.p. 
masses were gently detached from organs and abdomi-
nal wall, removed and weighed. Tumor weight inhibition 
percentage (TWI  %) was used to assess the antitumor 
activity of CpG-ODN1826. Tumor-free treated mice 
at the end of experiment were considered cured. Drug 
treatment toxicity was determined as body weight loss 
and lethal toxicity.
At the end of the experiment with late-stage STO 
tumors, peritoneal washings were done by i.p. injection 
and withdrawal of 5 ml saline using heparinised syringe 
with 22-gauge needle. The lavage fluid was then trans-
ferred into centrifuge tubes and maintained on ice until 
immunological analysis.
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Flow cytometry and IgM purification
Leukocyte population was evaluated in peritoneal wash-
ing and spleen cell suspension obtained from mice 
bearing late-stage STO tumors, treated or not with CpG-
ODN. Briefly, after red blood cells lysis, cells were stained 
(30 min at 4 °C) with the following antibodies: CD45AP-
CeFluor780 (clone 30-F11; eBioscience, San Diego, 
CA, USA); CD49bFITC (clone DX5; Miltenyi, Bergisch 
Gladbach, Germany); CD11bPECy5 (clone M1/70; eBio-
science); Ly6G/GR-1PE (clone RB6-8C5; Southern Bio-
tech, Birmingham, AL, USA); F4/80PerCPCy5.5 (clone 
BM8; eBioscience); CD11cPECy7 (clone N418; eBiosci-
ence); CD11bPerCPCy5.5 (clone M1/70; eBioscience); 
CD5PEVio770 (clone 53-7.3; Miltenyi); CD23FITC (clone 
B3B4; Miltenyi); CD19APC (clone 6D5, Miltenyi). Rat 
anti-mouse CD16/CD32 monoclonal antibody (eBio-
sciences) was used to prevent nonspecific binding to 
mouse Fc receptors. Cells were examined by FACSCanto 
flow cytometer (Becton–Dickinson, San Jose, CA, USA) 
and data analyzed using FlowJo software (TreeStar Inc., 
Ashland, OR, USA). Analyses were performed gating on 
CD45 + cells after doublet exclusion.
Moreover, IgM were purified from peritoneal lavages 
by affinity chromatography on HiTrap IgM Purifica-
tion HP column (GE HealthCare, Uppsala, Sweden). The 
concentration of purified IgM was determined by Pierce 
BCA Protein Assay Kit (Thermo Scientific, Waltham, 
MA USA).
Statistical analysis
The percentage of ascites-free mice over time was esti-
mated by the Kaplan–Meier product limit method and 
compared by the log-rank test. Student’s t test was used 
to assess differences in tumor weights and immune infil-
trate in control versus CpG-ODN1826-treated mice. All 
tests were two-sided. P values <0.05 were considered sta-
tistically significant.
Results
The efficacy of CpG-ODN1826 (delivered i.p. qdx5d/
wx4w) was initially tested in SCID mice i.p. bearing early-
stage (i.e., 4  days after cell inoculum) MesoII tumors. 
Following i.p. injection of MesoII cells, all control (saline-
treated) mice developed ascites in a median time of 
42.5  days (range 42–48  days) and underwent increased 
abdominal volume and body weight (Fig.  2a,b). At nec-
ropsy, hemorrhagic effusion, together with a large tumor 
mass at omentum, was found in all control mice (6/6). In 
addition, multifocal small nodules, widely scattered on 
mesentery, diaphragm and abdominal organs, were pre-
sent. The mean (±SD) volume of removed effusion was 
2.05 ± 1.4 ml and the mean (±SD) weight of solid masses 
was 1460 ±  776  mg (Table  1). Strikingly, 102  days after 
the last administration of CpG-ODN1826, no treated ani-
mal had yet presented ascites (T/C >308 %; P = 0.0004) 
(Fig.  2a). Moreover, no evidence of tumor masses was 
found at necropsy (Table 1). Body weight loss in treated 
animals did not exceed 10 % (Fig. 2b) and no toxic death 
occurred. Thus, CpG-ODN1826 safely cured 100 % mice 
(6/6), exhibiting impressive efficacy in early-stage MesoII 
orthotopic xenografts.
CpG-ODN1826 was then delivered to SCID mice i.p 
bearing early-stage (4  days after cell inoculum) STO 
tumors under the same treatment conditions used for 
Fig. 1 Schematic experimental timeline of DMPM orthotopic model generation, administration of CpG-ODN1826, and sacrifice of mice. Orthotopic 
models were generated by injecting exponentially growing MesoII and STO cells into the peritoneum of SCID mice. The day after cell injection, 
mice were randomized to receive saline or CpG-ODN1826 (20 µg/mouse, qdx5/wx4w): CpG-ODN1826 treatment started 4 days (STO and MesoII 
early-stage tumors) or 11 days (STO late-stage tumors) after cell injection. MesoII cell-injected mice were sacrificed as ascites was evident; STO cell-
injected mice were sacrificed the day after the last CpG-ODN1826 treatment
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MesoII. At day 30 from cell inoculum, i.e. the day after 
the last CpG-ODN1826 administration, animals were 
sacrificed. At necropsy, all control mice (6/6) showed 
considerable tumor growth with the same pattern of 
distribution of neoplastic masses observed with Mes-
oII. Conversely, the majority of CpG-ODN1826-treated 
mice (4/6) were macroscopically tumor-free. The mean 
(±SD) weight of tumor masses was 695 ± 206 mg and 
43  ±  60  mg in control and treated mice, respectively, 
showing 94  % (P  =  0.00005) drug-induced tumor 
growth inhibition (Fig. 3a; Table 1). The agent was well 
tolerated with a maximum body weight loss of 13  % 
and no toxic death. The data indicate high efficacy of 
CpG-ODN1826 against early-stage STO orthotopic 
xenografts.
Based on such excellent results, the antitumor effect 
of CpG-ODN1826 was tested against the STO model at 
a late-stage of development (i.e., 11 days after cell inoc-
ulum). The day after the last CpG-ODN1826 admin-
istration, the animals were sacrificed. At necropsy, i.p. 
DMPM growth was found in all control and treated mice. 
However, animals receiving CpG-ODN1826 presented 
a tumor burden significantly reduced with respect to 
controls. Specifically, the mean (±SD) weight of tumor 
masses collected from abdominal cavity was 1120 ±  55 
and 381  ±  99  mg (P  =  0.0009) in control and CpG-
ODN1826-treated mice, respectively (Fig.  3b; Table  1), 
indicating that the agent was able to reduce by 66 % the 
growth of STO orthotopic xenograft model even when 
treatment was started at an advanced stage of disease.
Fig. 2 Efficacy of i.p. CpG-ODN1826 (20 µg/mouse, qdx5d/wx4w) against orthotopic DMPM MesoII xenografts. a Kaplan–Meier plot of the percent-
age of ascites-free mice over time since i.p. MesoII cell injection. Mice (six animals/group) were randomized to receive saline (Δ) or CpG-ODN1826 
(▲). The treatment started 4 days after cell inoculum (early-stage tumors). b Body weight variations in the two experimental groups reported in 
panel (a)
Table 1 Antitumor effects of i.p. CpG-ODN1826 (20 µg/mouse, qdx5d/wx4w) against early- and late-stage DMPM ortho-
topic xenografts
MesoII and STO cells (2.5 × 107  and 107/mouse, respectively) were inoculated i.p. in female SCID mice on day 0. Animals were sacrificed at ascites onset (MesoII) or 
the day after the last CpG-ODN1826 administration (STO); i.p. tumor masses were removed and weighed
a Number of mice with i.p. macroscopic tumors out of number of DMPM cell-injected mice
b Tumor weight inhibition percentage in treated over control mice
c By Student’s t test over saline-treated control mice
Model Drug Treatment  
start (day)
Tumor takea Tumor weight (mg) TWI %b Pc
Median Mean ± SD
MesoII Saline 4 6/6 1360 1460 ± 776
CpG-ODN1826 0/6 – –
STO Saline 4 6/6 625 695 ± 206
CpG-ODN1826 2/6 0 43 ± 60 94 0.00005
Saline 11 10/10 996 1120 ± 550
CpG-ODN1826 10/10 340 381 ± 99 66 0.0009
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At the end of the experiment, the composition of peri-
toneal immune cell infiltrate from control and CpG-
ODN1826-treated STO-bearing mice (4 animals/group) 
was analyzed by flow cytometry. Specifically, the per-
centage of macrophages (CD11b+  F4/80high), granu-
locytes (CD11b+ Ly6G+), NK (CD49b+) and dendritic 
cells (DC) (CD11b+  CD11c+) was evaluated among 
CD45+  gated cells. A strong increase of macrophages 
(CD11b+  F4/80high) was observed in CpG-ODN1826-
treated mice as compared to untreated mice (mean ± SD: 
69.1 ± 4.5 % versus 20.1 ± 4.6 %; P = 0.0003) (Fig. 4a). In 
parallel, a reduction of granulocytes (CD11b+  Ly6G+) 
(mean  ±  SD: 12.3  ±  1.3  % in CpG-ODN1826-treated 
versus 42.0 ±  9.7  % in control mice; P =  0.023) and of 
CD11b + F4/80low cells, which include monocytes and/
or macrophage precursors, (mean ± SD: 1.7 ± 0.5 % in 
CpG-ODN1826-treated versus 17.4 ± 2.8 % in untreated 
mice; P = 0.0016) was detected (Fig. 4a). The frequency 
of NK cells (CD49b+) and DC (CD11b+ CD11c+) was 
similar in the two experimental groups (Fig.  4a). Flow 
cytometry analysis was also performed on splenocytes 
obtained from the same animals. No significant differ-
ences in the percentage of monocytes, macrophages, 
granulocytes, NK cells and DC were observed (data not 
shown), suggesting that CpG-ODN1826 treatment modi-
fied the composition of leukocyte infiltrate only locally.
SCID mice are characterized by the absence, or a 
marked reduction, of conventional B lymphocytes and 
by the presence of B-1 cells, a B lymphocyte subpopula-
tion residing in the peritoneal and pleural cavities, which 
is nearly the only source of natural antibodies (IgM) in 
these animals [10, 11]. Since CpG-ODN1826 has been 
demonstrated to interact with B-1 lymphocytes [12, 13], 
the level of IgM, as a marker of CpG-ODN activity on 
B-1 cells, was assessed in peritoneal lavages obtained 
from CpG-ODN1826-treated and control mice. A sig-
nificant reduction of IgM concentration (P = 0.029) was 
detected in CpG-ODN1826-treated mice as compared 
to untreated mice (Fig.  4b). To confirm such an unpre-
dicted result, we carried out an additional experiment 
in late-stage STO bearing mice, under the same treat-
ment conditions, to directly assess the percentage of 
B-1 cells, together with IgM levels, in peritoneal lavages. 
Flow cytometry analysis revealed a marked reduction of 
B-1cells (CD19+  CD11b+  CD23−), expressing or not 
CD5, and a significant decrease of IgM concentration 
(11 ±  2.6 µg/ml versus 27.6 ±  3.1 µg/ml, P =  0.015) in 
CpG-ODN1826-treated mice as compared to controls 
(Fig. 4b).
Discussion
Since the biology of DMPM is largely unknown, and the 
cellular and molecular mechanisms responsible for its 
clinical aggressiveness and relative chemoresistance have 
not yet been elucidated, the identification of novel thera-
peutic targets for the design of more efficient treatment 
approaches remains a main challenge. The need for novel 
therapeutic strategies is also highlighted by statistical 
projections of mesothelioma-related deaths, which pre-
dict continuing increases in many countries [14], mainly 
as a late consequence of the widespread use of asbestos. 
In addition, the lack of DMPM experimental models rep-
resents an important obstacle for the preclinical develop-
ment of novel therapeutics.
In the present study, we assessed the efficacy of CpG-
ODN1826 in two DMPM orthotopic xenografts (MesoII 
Fig. 3 Efficacy of i.p. CpG-ODN1826 (20 µg/mouse, qdx5d/wx4w) against orthotopic DMPM STO xenografts. a Orthotopic STO tumor weight 
distribution. Mice (six animals/group) were randomized to receive saline or CpG-ODN1826. The treatment started 4 days after cell injection (early-
stage tumors). b Mice (ten animals/group) were randomized to receive saline or CpG-ODN1826. The treatment started 11 days after cell injection 
(late-stage tumors)
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and STO), which properly recapitulate the dissemina-
tion pattern in the peritoneal cavity of human DMPM 
[8] and, for this reason, represent valuable models for 
investigating novel therapeutics. As single agent, CpG-
ODN1826 displayed significant antitumor activity against 
both early- and late-stage DMPM xenograft models. 
Specifically, CpG-ODN1826, delivered i.p. qdx5/wx4w, 
completely abolished or markedly impaired take and 
growth of DMPM models in the abdominal cavity when 
treatment started a few days after tumor cell inoculum in 
SCID mice. In addition, in MesoII-bearing mice, CpG-
ODN1826 was able to considerably lengthening ascites-
free survival. In fact, no sign of ascites was appreciable 
in treated animals until the end of the experiment (i.e., 
102  days after the last CpG-ODN1826 administration). 
This finding is in trend with the reported ability of the 
agent to restrain ascites by drainage and prolong the 
life span of mice bearing established ascites from i.p. 
Fig. 4 Flow cytometric and affinity chromatography analyses of cellular and humoral peritoneal immunity in CpG-ODN1826 (20 µg/mouse, qdx5d/
wx4w) treated late-stage STO tumor-bearing mice. a Percentage of NK cells (CD49b+), monocytes/macrophage precursors (CD11b+ F4/80low), DC 
(CD11b+ CD11c+), granulocytes (CD11b+ Ly6G+), macrophages (CD11b+ F4/80high) among CD45 + cells and dot plots of significantly modu-
lated subpopulations. b Percentage and dot plots of B-1 cells (CD19 + gated on CD11b+ CD23- among CD45 + FSClowSSClow cells) expressing 
or not CD5 (left); IgM concentration (right). All histograms represent pooled data (mean ± SE) from peritoneal lavages of 4 mice/group. *P < 0.05; 
**P < 0.01; ***P < 0.001
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ovarian carcinoma xenografts [15, 16]. Angiogenic fac-
tors produced by tumors can allow fluid accumulation 
by increasing the permeability of micro-vessels in the 
serosa. However, in the i.p. ovarian carcinoma xenograft 
model, the levels of vascular endothelial growth factor, 
platelet derived growth factor and basic fibroblast growth 
factor in i.p. fluid were not affected by CpG-ODN1826 
treatment [15], suggesting other possible mechanisms 
through which the agent inhibits ascites development.
When the therapeutic effects of CpG-ODN1826 were 
assessed in late-stage STO xenografts, a significant tumor 
growth impairment was observed, thus indicating that 
the agent maintains a remarkable antitumor activity even 
against established tumors, in the presence of an accept-
able toxicity. It should be noted that the growth inhibi-
tion of human DMPM xenografts was observed in mice 
injected with a murine specific TLR9 agonist, making 
unlikely that the observed antitumor activity was ascrib-
able to a direct interaction between CpG-ODN1826 
and tumor cells, as different CpG-ODN sequences are 
required for stimulation of mouse and human TLR9-pos-
itive cells.
Flow cytometry analysis of peritoneal infiltrate from 
late-stage STO-bearing mice revealed a strong increase 
of macrophage infiltration after CpG-ODN treatment. 
It is well known that tumor recruited macrophages can 
support tumor progression [17]; conversely, macrophages 
activated by microbial products (i.e., TLR ligands and 
NOD specific agonists) and pro-inflammatory cytokines 
(i.e., Interferon gamma and Tumor necrosis factor (TNF) 
alpha) have shown antitumor activity [18]. In this con-
text, macrophages locally activated by CpG-ODN1826 in 
the peritoneal cavity may promote killing of tumor cells 
through a variety of mechanisms. Specifically, the anti-
tumor effect can be mediated by the production of cyto-
toxic and anti-proliferative molecules, such as reactive 
oxygen and reactive nitrogen intermediates, which can 
induce DNA damage [19], and TNF superfamily mem-
bers, which can mediate apoptosis of cells expressing the 
respective receptors [20, 21]. Moreover, macrophages 
might indirectly enhance NK-mediated antitumor activ-
ity by secreting chemokines, such as CCL5 and CXCL10, 
and cytokines, such IL-12 and IL-23.
Differences between CpG-ODN1826- and saline-
treated mice were also observed through the analysis 
of IgM in peritoneal lavages, with a strong reduction 
of IgM abundance in CpG-ODN-treated mice. Such 
IgM reduction might be related to the ability of CpG-
ODN to induce differentiation of peritoneal B-1 cells 
into myeloid-like phagocytic cells, as recently reported 
[22]. Accordingly, flow cytometry analysis using a panel 
of antibodies to detect B-1 cells in peritoneal lavages 
revealed that this population almost disappeared from 
peritoneal cavity of mice treated with CpG-ODN1826. 
However, since the role of B-1 in tumor growth has been 
poorly investigated, we cannot define whether CpG-
ODN1826-induced differentiation of B-1 cells might be 
involved in DMPM xenograft growth inhibition. Interest-
ingly, recent studies attributed to B-1 cells an important 
role in tumor progression in a melanoma model, show-
ing that physical contact between B-1 lymphocytes and 
tumor cells was responsible for changes in the expression 
of metastasis-associated genes [23, 24].
In summary, the impressive efficacy displayed by CpG-
ODN1826 in mice with low tumor burden suggests a 
possible clinical utility of the agent as local adjuvant ther-
apy in DMPM patients who underwent CRS +  HIPEC. 
In addition, the finding that CpG-ODN1826 maintains 
antitumor activity also against late-stage DMPM xeno-
grafts, together with previous evidence indicating that 
the agent synergizes with several antitumor drugs, either 
cytotoxic (gemcitabine, camptothecins and cisplatin) [25] 
or target-specific (cetuximab) [16], highlights the possi-
bility that CpG-ODN1826 could have a role in combined 
strategies for treating patients who are not eligible for 
CRS +HIPEC.
Conclusions
DMPM is a rapidly fatal tumor with scanty therapeu-
tic options. Here we demonstrate for the first time that 
locally administered CpG-ODN1826, a synthetic DNA 
sequence recognized by TLR9 and able to induce innate/
adaptive immune response, displays significant antitu-
mor activity against early- and late-stage DMPM ortho-
topic xenograft models, in the absence of severe toxicity. 
These findings support the possible clinical relevance of 
a novel CpG-ODN1826-based immunotherapy approach 
for the disease. In this context, a deeper understanding 
of the determinants of CpG-ODN1826 activity will be of 
paramount importance for the definition of biomarkers 
for the selection of patients more likely to respond and 
maximize treatment benefits.
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